In metastatic triple-negative breast cancer patients with PD-L1–positive (expression of PD-L1 on the tumor-infiltrating immune cells ≥1% of tumor area), combination therapy with atezolizumab plus nab-paclitaxel led to a significantly longer progression free survival than placebo plus nab-paclitaxel (13). Here, CD274 is linked to neoplasm.